Epidemiology

Epidemiology	
% Estimated prevalence of chronic Hepatitis B infection (HBsAg+) ⁱ	1.62 [1.29–2.03]
Estimated prevalence of chronic HCV infection ^{III} (%) ^{IIII}	0.57
Estimated prevalence of chronic HCV infection (N) ⁱⁱⁱ	182 000
HCV prevalence among PWID [mean[95% CI]] ^{iv}	31.7 [22.6-41.6]
Hepatitis specific mortality rate per 100 000 ^v (2013)	0.016
Liver cancer incidence (ASR ^{vi}) per 100 000 ^{vii} (2012)	5.2

Governance	
Presence of a focal point	Yes
Presence of STAG	FP*
Involvement of civil society	No
Units to implement national response	FP*
NSP (published or drafted)	Yes
	Yes
Estimating cost to implement the NSP	
Fund available for the NSP	No 50*
Impact targets set	FP*
Service coverage targets set	FP*
Policies for stigma and discrimination	Yes
A system for Hepatitis prevention, testing, care and	NI
treatment services integrated at community, primary,	No
secondary and tertiary care levels has been defined	
Core hepatitis competencies of different cadres of	NI -
health workers at different levels of the health system	No
been defined considering task shifting options	
Training and supervisory needs of health workers been defined	No
An investment case for an enhanced viral hepatitis response been developed **	No
A specific portion of National health budget had been	
allocated to viral hepatitis prevention, care and	No
treatment?	NO
A set of essential viral hepatitis interventions been	
defined to be included in the national social / health	No
insurance package	NO
FP*: Future plans	
Surveillance	
National surveillance system for viral hepatitis	No
	No
An inventory of existing data and sources of data on viral hopatitis been made	NO
viral hepatitis been made	

Testing policies Official guidance on HBV and/or HCV	and guidelines which test to use for diagnosing	Yes
Official guidance on testing pregnant women for HBV		No
Official guidance on testing people who inject drugs (PWID) for HCV		Yes
Official guidance or protocols for all people diagnosed with HBV and/or HCV to be routinely referred for treatment and care		No
National coverage targets	Hepatitis B testing coverage of selected populations	Yes
been set for the following indicators	Hepatitis C testing coverage of selected populations	Yes
	Policies for screening of selected population groups at increased risk	No
Presence of national policies and guidelines	A policy for mandatory screening of all blood donations for Hepatitis B and C	Yes
for priority interventions available and in line with global standards for the	A policy for referral of all blood donors with positive screening results for Hepatitis B and C confirmatory testing and case management	No
following	Guidelines for diagnostic testing for Hepatitis B	No
	Guidelines for diagnostic testing for Hepatitis C	No
Baseline values	Percentage of blood donors screened for Hepatitis B and C	No
been determined for the following global indicators	Percentage of health facilities that implement the policy of 100% single use (or safety engineered) injection devices	No
Infrastructure for Number of facilitie able to offer service testing for both H HBsAg) and HCV (HCV)	es that are Number of facilities ological able to offer nucle HBV (i.e. testing (NAT) for bot i.e. Anti- HBV DNA) and HCV	eic acid h HBV (i.e. (i.e. HCV
	Drimary	

Primary level Secondary

Primary level (i.e. Secondary

Treatment policies and guidelines	
Tenofovir or Entecavir as the first line of treatment for HBV	No
Anti-nucleoside/nucleotide analogues are available for the treatment of hepatitis B	No
interferon-free (INF-free) direct-acting antiviral (DAA) are the regimens considered the first line of treatment for patients with chronic hepatitis C	No
Current treatment policy for people with chronic HCV	FP*
Current situation in terms of registration of Tenofovir or Entecavir specifically for HBV infection Current situation in terms of registration of	Yes**
medicines used in IFN-free DAA regimens for HCV infection	No
Tender (national or multinational) to launch price negotiations with pharmaceutical companies for HBV and/or HCV treatment	No
Hepatitis B treatment coverage	No No
Hepatitis C treatment coverage Guidelines for Hepatitis B treatment	No
Guidelines for Hepatitis C treatment	No
A strategy for achieving the best price for medicines and diagnostics been formulated and pursued	No
Treatment Estimates	
Estimate of the total number of people on antiviral treatment for HBV for the years 2013	NA
Estimate of the total number of people on antiviral treatment for HBV for the years 2015	NA
Estimate of the total number of people initiated on antiviral treatment for HCV for the years 2013	NA
Estimate of the total number of people initiated on antiviral treatment for HCV for the years 2015	NA
Estimate of the total number of people planned and budgeted for treatment of HBV infection in 2017	NA
Estimate of the total number of people planned and budgeted for treatment of HCV infection in 2017	NA
FP*: Policy not established, but plan is to establish one b Yes**: One or more of these medicines have been regist but only for HCV	-

Prevention		No
National	Hepatitis B vaccination of health workers	No
coverage targets been set for the	Safe injections in health care settings	No
following indicators	Targets for number of needles- syringes distributed to PWID per year	No
- /	A policy for Hepatitis B vaccination of health workers	Yes
Presence of national policies and guidelines for priority interventions	A policy to integrate Hepatitis B vaccination in services targeting people who inject drugs, men who have sex with men and sex workers	Yes
available and in line with global standards for the following	A policy for use of safe injections (or safety engineered devices) in health care settings to prevent transmission of blood borne infections	No
Baseline values	Coverage of hepatitis B vaccination of health workers,	No
been determined for the following	For countries with significant PWID populations, coverage of needles- syringe distribution	No
global indicators	For countries with significant PWID populations, HBV vaccination	No

HCV Elimination Targets			
	2017	2019	2020
Prevalence of Chronic HCV			
(%)	0.54%	0.50%	0.46%
Chronic HCV (N)	184	177	
	000	000	167 000
Diagnosed with HCV (%)	14.33%	18.2%	21.03%
Diagnosed with HCV (N)	26 300	32 300	35 200
HCV patients treated (%)	0.22%	1.80%	5.45%
HCV patients treated (N)	400	3 200	9 100
Number of new infections	4 700	3 300	1 300

Saturday 5th of July 2025 10:27:34 AM